相似文献
1
Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy.
Am J Hematol. 2019 Aug;94(8):E209-E213. doi: 10.1002/ajh.25505. Epub 2019 May 21.
2
Late Events After CD-19 CAR-T Treatment.
Biol Blood Marrow Transplant. 2020 Jan;26(1):e1-e2. doi: 10.1016/j.bbmt.2019.10.020. Epub 2019 Oct 25.
3
Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma.
Blood. 2018 Aug 23;132(8):777-781. doi: 10.1182/blood-2018-04-839217. Epub 2018 Jun 18.
4
Impact of the kinetics of circulating anti-CD19 CAR-T cells and their populations on the outcome of DLBCL patients.
Blood Cancer J. 2024 May 17;14(1):83. doi: 10.1038/s41408-024-01065-z.
5
CAR T cell therapy for B-cell lymphomas.
Best Pract Res Clin Haematol. 2018 Jun;31(2):135-146. doi: 10.1016/j.beha.2018.04.001. Epub 2018 Apr 11.
6
Stuttering as the first sign of CAR-T-cell-related encephalopathy syndrome (CRES).
J Cancer Res Clin Oncol. 2019 Jul;145(7):1917-1918. doi: 10.1007/s00432-018-2818-y. Epub 2018 Dec 11.
7
A second round of anti-CD19 CAR T-cell therapy in diffuse large B-cell lymphoma: when persistence pays off.
Leuk Lymphoma. 2024 Jun;65(6):868-871. doi: 10.1080/10428194.2024.2325188. Epub 2024 Mar 5.
8
CAR T-cell therapy in refractory large B-cell lymphoma.
Lancet Oncol. 2018 Jan;19(1):e19. doi: 10.1016/S1470-2045(17)30928-2. Epub 2017 Dec 14.
9
[CAR-T cells in lymphomas: Current and evolving role].
Bull Cancer. 2021 Oct;108(10S):S28-S39. doi: 10.1016/j.bulcan.2021.04.022.
10
Open access? Widening access to chimeric antigen receptor (CAR) therapy for ALL.
Exp Hematol. 2018 Oct;66:5-16. doi: 10.1016/j.exphem.2018.07.002. Epub 2018 Jul 20.
引用本文的文献
1
Therapeutic landscape of primary refractory and relapsed diffuse large B-cell lymphoma: Recent advances and emerging therapies.
J Hematol Oncol. 2025 Jul 1;18(1):68. doi: 10.1186/s13045-025-01702-5.
2
An exploration of the initiation time and patient selection of PD-1 inhibitors/PD-1 inhibitors combined with chemotherapy as salvage therapy in R/R DLBCL patients after anti-CD19-CAR T-cell therapy.
Cell Transplant. 2025 Jan-Dec;34:9636897251338713. doi: 10.1177/09636897251338713. Epub 2025 Jun 5.
3
Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphoma.
Blood Adv. 2025 Aug 12;9(15):3955-3966. doi: 10.1182/bloodadvances.2024015719.
4
Be cautious to adopt a second CAR T-cell infusion after failure of CD19/CD22 cocktail CAR T-cell therapy in relapsed/refractory B-NHL.
Cancer Immunol Immunother. 2025 Mar 22;74(5):156. doi: 10.1007/s00262-025-04001-7.
5
Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study.
Blood. 2025 Apr 3;145(14):1498-1509. doi: 10.1182/blood.2024027044.
6
Afatinib boosts CAR-T cell antitumor therapeutic efficacy via metabolism and fate reprogramming.
J Immunother Cancer. 2024 Nov 17;12(11):e009949. doi: 10.1136/jitc-2024-009949.
7
Several factors that predict the outcome of large B-cell lymphoma patients who relapse/progress after chimeric antigen receptor (CAR) T-cell therapy can be identified before cell administration.
Cancer Med. 2024 Sep;13(17):e70138. doi: 10.1002/cam4.70138.
8
The basic biology of NK cells and its application in tumor immunotherapy.
Front Immunol. 2024 Aug 16;15:1420205. doi: 10.3389/fimmu.2024.1420205. eCollection 2024.
9
Outcomes of patients with R/R B-cell NHL and limited (<5 sites) pre-CART disease bridged with or without radiotherapy.
Blood Adv. 2024 Sep 24;8(18):4877-4885. doi: 10.1182/bloodadvances.2024013647.
10
Salvage CD20-SD-CART therapy in aggressive B-cell lymphoma after CD19 CART treatment failure.
Front Oncol. 2024 Jun 25;14:1376490. doi: 10.3389/fonc.2024.1376490. eCollection 2024.
本文引用的文献
1
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
N Engl J Med. 2019 Jan 3;380(1):45-56. doi: 10.1056/NEJMoa1804980. Epub 2018 Dec 1.
2
Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma.
Blood. 2018 Aug 23;132(8):777-781. doi: 10.1182/blood-2018-04-839217. Epub 2018 Jun 18.
3
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.
N Engl J Med. 2017 Dec 28;377(26):2531-2544. doi: 10.1056/NEJMoa1707447. Epub 2017 Dec 10.
4
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.
Blood. 2017 Oct 19;130(16):1800-1808. doi: 10.1182/blood-2017-03-769620. Epub 2017 Aug 3.
5
Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study.
Bone Marrow Transplant. 2017 Feb;52(2):216-221. doi: 10.1038/bmt.2016.213. Epub 2016 Sep 19.
6
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
J Clin Oncol. 2010 Sep 20;28(27):4184-90. doi: 10.1200/JCO.2010.28.1618. Epub 2010 Jul 26.
Zotero 插件